It has also been reported that long-term selective estrogen receptor modulator (SERM) administration may increase the risk of NAFLD development, with fatty liver reported in 48.5% of tamoxifen-treated and 50.2% of toremifene-treated breast cancer patients at 60 months [19]. Here, ESR1 is linked to breast carcinoma.